How Does Xyzal Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Xyzal Works
- Active Ingredient: Levocetirizine dihydrochloride 5 mg, the active R‑enantiomer of cetirizine.
- Mechanism: Selective inverse agonist at peripheral H1 receptors – blocks histamine, reducing sneezing, rhinorrhoea, and urticaria.
- Onset & Duration: Relief begins within 1 hour; effects last 24 hours, enabling once‑daily dosing.
- Metabolism & Excretion: Minimally metabolised; 85% excreted unchanged in urine; half‑life 7–10 hours. Dose adjustment needed in renal impairment.
- Safety: Low sedation (comparable to placebo); contraindicated in severe renal disease requiring dialysis.
Xyzal (levocetirizine) is a modern, non‑sedating antihistamine that provides effective relief from allergic rhinitis and chronic urticaria. This guide explains how it works in the body to alleviate allergy symptoms.
Important Medical Advice
Do not take Xyzal if you are allergic to levocetirizine, cetirizine, hydroxyzine or any tablet excipient, or if you have severe kidney disease requiring dialysis. Consult your doctor before use if you have difficulty urinating (e.g., spinal cord injury, enlarged prostate) or epilepsy. Seek immediate medical help if you experience signs of a serious allergic reaction: swelling of the face/mouth, difficulty breathing, or collapse.
Chemical Composition & Molecular Structure of Xyzal
Xyzal 5 mg film‑coated tablets contain the active substance levocetirizine dihydrochloride, the (R)‑enantiomer of cetirizine. Its chemical name is 2‑[2‑[4‑[(R)‑(4‑chlorophenyl)phenylmethyl]piperazin‑1‑yl]ethoxy]acetic acid dihydrochloride. The empirical formula is C21H25ClN2O3 · 2HCl, with a molecular weight of 461.8.
Structural Details
Selective H1 receptor inverse agonist
The piperazine ring and carboxylic acid side chain confer high affinity for the H1 receptor. The (R)‑enantiomer has approximately 30‑fold higher affinity than the (S)‑form.
Microcrystalline cellulose, lactose monohydrate, colloidal anhydrous silica, magnesium stearate, hypromellose (E464), titanium dioxide (E171), macrogol 400.
The tablet core and coating ensure stability and controlled release; lactose content is low (normally well tolerated).
Key Pharmaceutical Properties
| Property | Levocetirizine |
|---|---|
| Lipophilicity (logP) | 1.5 |
| Protein binding | 90% |
| pKa | 3.2 (carboxylic acid), 8.0 (piperazine) |
| Bioavailability | ~85% |
| Receptor affinity (Ki) | ~3 nmol/L (H1) |
🗒️ Pharmaceutical insight: The high water solubility of levocetirizine dihydrochloride promotes rapid dissolution in the gastrointestinal tract, contributing to its fast absorption.
Mechanism of Action: Xyzal's Antihistamine Pathways
Levocetirizine acts as a potent, selective inverse agonist at the histamine H1 receptor. By binding to the receptor, it stabilises its inactive conformation, preventing G‑protein activation and downstream signalling normally triggered by histamine.
- H1 receptor blockade: Histamine released from mast cells during allergic reactions binds to H1 receptors on endothelial cells and sensory nerves. Levocetirizine competitively inhibits this binding, reducing vasodilation, vascular permeability, and itching.
- Inverse agonism: Unlike neutral antagonists, levocetirizine reduces basal H1 receptor activity, further dampening allergic inflammation.
- No anticholinergic or antiserotonergic effects: At therapeutic doses, it does not interact with muscarinic or serotonin receptors, minimising dry mouth and sedation compared to first‑generation antihistamines.
| Feature | Levocetirizine |
|---|---|
| Onset of action | 1 hour |
| Peak effect | 2–4 hours |
| Duration | 24 hours (once‑daily dosing) |
🗒️ Physiological insight: Because levocetirizine targets only peripheral H1 receptors and penetrates the blood‑brain barrier poorly, it causes minimal sedation – a key advantage over older antihistamines.
Absorption & Distribution of Xyzal (Pharmacokinetics)
Following oral administration, levocetirizine is rapidly and extensively absorbed. Peak plasma concentrations (Cmax ~270 ng/mL after 5 mg) are reached in approximately 0.9 hours (tmax). Food does not affect the extent of absorption but may slightly delay tmax.
Distribution
Levocetirizine is highly protein‑bound (90%), mainly to albumin. Its volume of distribution is about 0.4 L/kg, indicating limited extravascular distribution. It crosses the placenta and is excreted into breast milk in small amounts.
Special populations
In patients with mild to moderate renal impairment (CrCl 30–80 mL/min), half‑life is prolonged; dose reduction is recommended. Hepatic impairment alone does not significantly alter pharmacokinetics.
Metabolic Effects & Elimination of Xyzal
Levocetirizine undergoes minimal hepatic metabolism (<14% of the dose) via oxidation (aromatic ring oxidation, N‑ and O‑dealkylation) to inactive metabolites. It does not inhibit or induce cytochrome P450 enzymes, making drug‑drug interactions unlikely.
Elimination: About 85% of an oral dose is excreted unchanged in the urine; another 13% appears in faeces. The elimination half‑life averages 8–10 hours in healthy adults, but is prolonged in renal impairment (up to 24 hours in severe impairment).
⚠️ Metabolic caution: Because levocetirizine is primarily renally cleared, patients with creatinine clearance below 50 mL/min require dose adjustment (e.g., 2.5 mg once daily). It is contraindicated if dialysis is needed.
Clinical Efficacy of Xyzal in Allergic Rhinitis & Urticaria
Xyzal is indicated for the symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis) and chronic idiopathic urticaria. Large randomised controlled trials have demonstrated:
- Allergic rhinitis: Significant reduction in total symptom scores (sneezing, rhinorrhoea, nasal itching, congestion) compared to placebo, with onset within 1 hour and sustained effect over 24 hours.
- Chronic urticaria: Reduction in pruritus severity and number of hives, improving quality of life and sleep.
- SMART therapy analogy: When used regularly, it prevents breakthrough symptoms, similar to maintenance therapy in asthma.
In comparative studies, levocetirizine 5 mg once daily was at least as effective as cetirizine 10 mg, with a lower incidence of somnolence.
Xyzal FAQs
How long does Xyzal take to start working?
Levocetirizine begins to relieve symptoms within 1 hour of taking the tablet. Peak effect occurs at 2–4 hours, and the effect lasts for 24 hours.
Can I take Xyzal with food?
Yes, Xyzal can be taken with or without food. Food may slightly delay absorption but does not reduce the overall amount absorbed.
Is Xyzal safe for children?
Xyzal 5 mg film‑coated tablets are licensed for children aged 6 years and above. The dose is one tablet daily. For younger children, other formulations may be more suitable.
Can I drink alcohol while taking Xyzal?
Caution is advised. Although levocetirizine is minimally sedating, alcohol may increase the risk of drowsiness and reduced alertness. Avoid excessive alcohol.
What should I do if I miss a dose?
Take your next dose at the normal time. Do not take a double dose to make up for a forgotten one. If you are unsure, consult your pharmacist.
Need Xyzal with Expert Guidance?
If you suffer from allergies and think Xyzal may help, a UK‑registered doctor can assess your symptoms and provide a prescription online.
Secure Prescription & Next-Day Delivery
MHRA‑compliant | GPhC‑registered pharmacy | Discreet packaging | UK‑registered doctors
Start Allergy ConsultationRelated Xyzal Guides
Clinical References & Sources
Medical Content Manager
Nabeel is a co‑founder and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up‑to‑date.
Medical Doctor
Dr. Feroz is a GMC‑registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.
Medical Director
Usman is a co‑founder and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.
Review Date: 12 March 2026
Next Review: 12 September 2026
Published on: 12 March 2026
Last Updated: 12 March 2026